Showing 492 Results
In a Health Affairs Blog article, NPC and MIT researchers outline how a new rule from CMS may fall short of what is needed to improve patient access to durable cell and gene therapies that target…
The U.S. spends twice as much per person on health care compared to other wealthy countries. While higher U.S. health care prices play a role in this disparity, they are not the only cause. A new NPC…
Researchers from Brigham and Women’s Hospital, Harvard Medical Center and NPC found that the potential for biased findings in RWE studies increases substantially in the absence of a rigorous and…
- Real-World Evidence
In a commentary for PharmaBoardroom, NPC's John M. O’Brien explains why we need a focused effort from all health care stakeholders to innovate on how we pay for vital medicines.
On a recent webcast, NPC Vice President of Health Services Research Kimberly Westrich discusses the importance of patient-centered care and the benefits and opportunities of incorporating patient…
Reforming health benefits by overhauling existing utilization management practices and adjusting patient cost-sharing to incentivize high-value care would help achieve more affordable, patient…
What's at risk if we limit innovation? Read the commentary from NPC's John O'Brien in Chain Drug Review.
The COVID-19 pandemic has put a spotlight on the pressing need to address social determinants of health (SDOH). NPC's Dr. Dubois examines the gaps within the existing evidence base and how to improve…
During a recent webinar, NPC President and CEO John M. O'Brien discusses how the Medicare Part D rebate system creates barriers to affordable care for patients.
A new study by NPC and the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center found that health insurance plans do not ask patients for input when developing specialty drug…
In a column published in Morning Consult, NPC's research team explains why potential government involvement in drug pricing would be unlikely to increase patient affordability.
- Health Spending
Michael Ciarametaro, Vice President of Research at NPC, reflects on how the scientific revolution of hepatitis C led to a corresponding reimbursement revolution that became a fertile ground for large…
NPC President and CEO John O'Brien discusses the IQVIA Institute’s new report and takes a closer look at the factors that are driving medication use and health care spending in the United States.
A research survey found that potential government involvement in drug pricing would be unlikely to increase patient affordability.
In this issue: meet NPC's new president and CEO, learn how we can tackle low-value care, what we need to know about the budget cap dilemma, and catch up on news you might have missed!
- E.V.I.dently® Newsletter
NPC Board Chair Michael Ryan says John M. O’Brien’s arrival as the new president and CEO of NPC reinforces a vital role the biopharmaceutical industry can play in the ongoing debate about health care…
- NPC News
NPC President and CEO John O'Brien discusses how prescription medicines and the pharmacists who provided them helped people stay healthy at home during the pandemic.
Research conducted by NPC and Discern Health found that shared decision-making and patient decision aid interventions do not always lead to reduced health care costs or utilization.
Three leading researchers detail steps to reduce low-value care in the latest edition of The American Journal of Managed Care. Their approach complements a similar effort, the Roadmap for Addressing…
- Low-Value Care
NPC's new president and CEO outlines his commitment to working with all partners, across all sectors, to improve our health care system.
- NPC News